Activation of cytotoxic lymphocytes through CD6 enhances killing of cancer cells.

Cancer immunology, immunotherapy : CII 2024 Jan 27

filter terms:

Immune checkpoint inhibitors (ICIs) have demonstrated efficacy and improved survival in a growing number of cancers. Despite their success, ICIs are associated with immune-related adverse events that can interfere with their use. Therefore, safer approaches are needed. CD6, expressed by T-lymphocytes and human NK cells, engages in cell-cell interactions by binding to its ligands CD166 (ALCAM) and CD318 (CDCP1). CD6 is a target protein for regulating immune responses and is required for the development of several mouse models of autoimmunity. Interestingly, CD6 is exclusively expressed on immune cells while CD318 is strongly expressed on most cancers. Here we demonstrate that disrupting the CD6-CD318 axis with UMCD6, an anti-CD6 monoclonal antibody, prolongs survival of mice in xenograft mouse models of human breast and prostate cancer, treated with infusions of human lymphocytes. Analysis of tumor-infiltrating immune cells showed that augmentation of lymphocyte cytotoxicity by UMCD6 is due to effects of this antibody on NK, NKT and CD8 + T cells. In particular, tumor-infiltrating cytotoxic lymphocytes from UMCD6-treated mice expressed higher levels of perforin and were found in higher proportions than those from IgG-treated mice. Moreover, RNA-seq analysis of human NK-92 cells treated with UMCD6 revealed that UMCD6 up-regulates the NKG2D-DAP10 receptor complex, important in NK cell activation, as well as its downstream target PI3K. Our results now describe the phenotypic changes that occur on immune cells upon treatment with UMCD6 and further confirm that the CD6-CD318 axis can regulate the activation state of cytotoxic lymphocytes and their positioning within the tumor microenvironment. © 2024. The Author(s).

Citation

Mikel Gurrea-Rubio, Qi Wu, M Asif Amin, Pei-Suen Tsou, Phillip L Campbell, Camila I Amarista, Yuzo Ikari, William D Brodie, Megan N Mattichak, Sei Muraoka, Peggy M Randon, Matthew E Lind, Jeffrey H Ruth, Yang Mao-Draayer, Shengli Ding, Xiling Shen, Laura A Cooney, Feng Lin, David A Fox. Activation of cytotoxic lymphocytes through CD6 enhances killing of cancer cells. Cancer immunology, immunotherapy : CII. 2024 Jan 27;73(2):34